Gilead Sciences has a Zacks Rank of #2 (Buy), while Vertex Pharmaceuticals has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that GILD likely has seen a stronger ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today. The company’s ...

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter financial results that handily beat Wall ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

Prior to joining Gilead Canada, Paul most recently led Jazz Pharmaceuticals, where he built their Canadian organization over ...

Stringer covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Gilead Sciences, and Apellis Pharmaceuticals. According to TipRanks, Stringer has an average return of 7.5% ...

Healthcare sector earnings report summary: 14 companies beat profit estimates, with major players like Viatris, Gilead ...

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

Dr. Ma currently serves as Executive Vice President, Pharmaceutical Development and Manufacturing at Gilead Sciences, Inc., ...